MedTrace Logo

Management of Patients With Neovascular Age-related Macular Degeneration Undergoing Cataract Surgery

NCT03944070 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2019-05-09

No results posted yet for this study

Summary

To-date there have been only very few studies to examine the effect of cataract surgery to patients with wet age-related macular degeneration. The evidence on the effects of cataract surgery in such patients suggests improvement of their visual function and quality of life, but at the same time a subclinical susceptibility to macular edema and exacerbation of the choroidal neovascularization. Therefore it is highly important to identify the optimum treatment regime, pursuing the best anatomical and functional postoperative results.

Conditions

  • Wet Macular Degeneration
  • Cataract Extraction

Interventions

DRUG

Ranibizumab

Intravitreal Ranibizumab is approved for the treatment of wet AMD. In this study we will compare an intensive injection protocol versus the standard treat and extend protocol in wet AMD patients undergoing cataract surgery.

Sponsors & Collaborators

  • Ophthalmica Eye Institute

    lead OTHER

Principal Investigators

  • Paris G Tranos, PhD · Head of Uveitis & Retinal Surgery Department, Ophthalmica Eye Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2020-01-31
Completion
2020-01-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03944070 on ClinicalTrials.gov